Literature DB >> 17344349

Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice.

Pablo D Becker1, Miriam Nörder, Carlos A Guzmán, Saul Grinstein.   

Abstract

Adamantylamide L-alanyl-D-isoglutamine (AdDP) is a synthetic adjuvant which belongs to the family of the desmuramyl peptides. AdDP exerts its adjuvant properties when it is administered either by the parenteral or by the mucosal route, leading to the elicitation of strong humoral responses at both the systemic and the mucosal levels. However, very little is known about the effect of AdDP on cellular immunity. Here we demonstrate that AdDP is able to stimulate cellular responses, which are characterized by the release of gamma interferon by CD8+ T cells when they are restimulated with a major histocompatibility complex class I-restricted peptide and strong in vivo lymphocyte-mediated cytotoxic activity. The capacity of AdDP to stimulate the elicitation of both cellular and humoral adaptive responses makes this adjuvant a promising tool for the development of mucosal vaccine formulations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344349      PMCID: PMC1865622          DOI: 10.1128/CVI.00316-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  24 in total

1.  Plasma cells for a lifetime?

Authors:  Rudolf A Manz; Andreas Radbruch
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

2.  Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

Authors:  Stefan Borsutzky; Valeria Fiorelli; Thomas Ebensen; Antonella Tripiciano; Faiza Rharbaoui; Arianna Scoglio; Claudia Link; Filomena Nappi; Michael Morr; Stefano Buttó; Aurelio Cafaro; Peter F Mühlradt; Barbara Ensoli; Carlos A Guzmán
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

3.  Bacterial ghosts are an efficient delivery system for DNA vaccines.

Authors:  Thomas Ebensen; Susanne Paukner; Claudia Link; Pavol Kudela; Carola de Domenico; Werner Lubitz; Carlos A Guzmán
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

4.  The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant.

Authors:  Pablo D Becker; Simona Fiorentini; Claudia Link; Giorgio Tosti; Thomas Ebensen; Arnaldo Caruso; Carlos A Guzmán
Journal:  Vaccine       Date:  2005-11-21       Impact factor: 3.641

5.  Production of specific antibody and T helper 1-dominant cytokine elicited by dendritic cells genetically modified with an adenovirus vector.

Authors:  N Inoue; S Kanaoka; S Yamasaki; S Arii; M Imamura
Journal:  Immunol Lett       Date:  1999-11-01       Impact factor: 3.685

6.  Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice.

Authors:  P D Becker; R S Corral; C A Guzmán; S Grinstein
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

7.  Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection.

Authors:  K N Masihi; W Brehmer; W Lange; E Ribi
Journal:  Int J Immunopharmacol       Date:  1983

8.  Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo.

Authors:  Ian F Hermans; Jonathan D Silk; Jianping Yang; Michael J Palmowski; Uzi Gileadi; Corinna McCarthy; Mariolina Salio; Franca Ronchese; Vincenzo Cerundolo
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

10.  Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae.

Authors:  Gustavo M Bertot; Pablo D Becker; Carlos A Guzmán; Saúl Grinstein
Journal:  J Infect Dis       Date:  2004-03-17       Impact factor: 5.226

View more
  2 in total

1.  Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.

Authors:  Miriam Nörder; Pablo D Becker; Ingo Drexler; Claudia Link; Volker Erfle; Carlos A Guzmán
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

2.  Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes.

Authors:  Pablo D Becker; Miriam Nörder; Sebastian Weissmann; Ronny Ljapoci; Volker Erfle; Ingo Drexler; Carlos A Guzmán
Journal:  Vaccines (Basel)       Date:  2014-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.